Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of LEO 43204 Gel in Actinic Keratosis
NCT02424305Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- May 2015
- Primary completion
- Jul 2015
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ingenol disoxate in actinic keratosis (AK) (3 arms), sponsored by LEO Pharma. Primary endpoints: Area under the plasma concentration versus time curve at 3 days and Peak Plasma Concentration at 3 days. Started May 2015; status: completed.
02
Drugs
ingenol disoxate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02424305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02424305.